Correlation Between Denali Therapeutics and Cytodyn

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Denali Therapeutics and Cytodyn at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Denali Therapeutics and Cytodyn into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Denali Therapeutics and Cytodyn, you can compare the effects of market volatilities on Denali Therapeutics and Cytodyn and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Denali Therapeutics with a short position of Cytodyn. Check out your portfolio center. Please also check ongoing floating volatility patterns of Denali Therapeutics and Cytodyn.

Diversification Opportunities for Denali Therapeutics and Cytodyn

0.42
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Denali and Cytodyn is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding Denali Therapeutics and Cytodyn in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cytodyn and Denali Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Denali Therapeutics are associated (or correlated) with Cytodyn. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cytodyn has no effect on the direction of Denali Therapeutics i.e., Denali Therapeutics and Cytodyn go up and down completely randomly.

Pair Corralation between Denali Therapeutics and Cytodyn

Given the investment horizon of 90 days Denali Therapeutics is expected to under-perform the Cytodyn. But the stock apears to be less risky and, when comparing its historical volatility, Denali Therapeutics is 1.22 times less risky than Cytodyn. The stock trades about -0.15 of its potential returns per unit of risk. The Cytodyn is currently generating about -0.06 of returns per unit of risk over similar time horizon. If you would invest  12.00  in Cytodyn on September 6, 2024 and sell it today you would lose (1.00) from holding Cytodyn or give up 8.33% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy95.45%
ValuesDaily Returns

Denali Therapeutics  vs.  Cytodyn

 Performance 
       Timeline  
Denali Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Denali Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong essential indicators, Denali Therapeutics is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders.
Cytodyn 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Cytodyn has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Denali Therapeutics and Cytodyn Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Denali Therapeutics and Cytodyn

The main advantage of trading using opposite Denali Therapeutics and Cytodyn positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Denali Therapeutics position performs unexpectedly, Cytodyn can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytodyn will offset losses from the drop in Cytodyn's long position.
The idea behind Denali Therapeutics and Cytodyn pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Other Complementary Tools

Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing